Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the pharmacokinetics (PK), safety and tolerability of 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) as compared to Granisetron IV Injection and Granisetron Tablet in healthy Volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Maxinase Life Sciences Ltd.
• Collaborator: Tri-Service General Hospital
• Treatments: Granisetron

Criteria

Inclusion Criteria:

1. Healthy males or females between the ages of 20-64 years

2. Body Mass Index (BMI) of 18.5 (inclusive) to 24 kg/m2; and a total body weight >45 kg

3. Accessible vein for blood sampling

4. No significant abnormalities in electrocardiogram (ECG) recording as per sites' local practice

5. No significant abnormalities in general physical examination as per sites' local practice

6. No significantly abnormal findings in laboratory assessments including hematology, biochemistry and urinalysis as per site's local practice

7. A signed and dated written informed consent must be obtained from the subject prior to study participation

8. Capable of understanding and willing to comply with study procedures

9. A negative serum pregnancy test before the first dose of study drug must be available for women of childbearing potential

Exclusion Criteria:

1. Females who are pregnant, breast-feeding or have positive pregnancy test

2. History of hypersensitivity to granisetron or its analogs

3. Subjects with nasal ulcer, septal perforation, or other nasal conditions that may interfere with nasal administration and determined by the investigator to be ineligible

4. Subjects with a QT interval greater than 500 ms or with acute ischemic changes or cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or by history

5. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or other significant disease or clinical findings at screening and determined by the investigator to be ineligible

6. Subjects with a history of drug and/or alcohol abuse within 12 months prior to dosing

7. Inability to read and/or sign the consent form

8. Treatment with any other investigational drug during the 4 weeks prior to the initial dosing for this study

9. Subjects who have donated or lost more than 250 ml blood within 2 months prior to the initial dosing for this study

10. Male and female subjects with reproductive potential who are not willing to use effective method of contraception. Use of hormonal contraceptive is not allowed during the study period

11. Clinical significant rhinitis or rhinorrhea at screening determined by the investigator to be ineligible

12. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to dosing of study medication

13. For subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.), 2 weeks abstinence is required

14. Conditions upon screening which might contraindicate or require that caution be used in the administration of granisetron